Systolic time interval as index of schedule--dependent doxorubicin cardiotoxicity in patients with acute myelogenous leukaemia
- PMID: 286623
- PMCID: PMC1598901
- DOI: 10.1136/bmj.1.6175.1392
Systolic time interval as index of schedule--dependent doxorubicin cardiotoxicity in patients with acute myelogenous leukaemia
Abstract
The ratio of the pre-ejection period to the left ventricular ejection time (PEP:LVET) was measured in two groups of patients with acute myeloblastic leukaemia (AML) receiving the anthracycline antibiotic doxorubicin (DXR). Patients receiving high doses of DXR per course (about 90 mg/m2) showed a significant increase in the PEP:LVET ratio irrespective of the total cumulative dose. At a lower dose per course (less than 50mg/m2) only patients who had a total cumulative dose of over 450 mg/m2 showed significant increases in ratio. ECG changes were seen in both groups of patients but did not correlate significantly with the dosage. These findings, which suggest that DXR cardiotoxicity is schedule dependent, are important in the design of schedules of DXR for treating cancer and in interpreting the changes in systolic time intervals (STIs) observed with different schedules. Measurement of the STI is a simple and convenient method of assessing DXR cardiotoxicity. While a total DXR dose of 550 mg/m2 should not normally be exceeded, by carefully monitoring the STI the recommended total dose may be exceeded safely in selected patients.
Similar articles
-
Evaluation of early doxorubicin-induced cardiotoxicity by means of systolic time intervals.Cancer Chemother Pharmacol. 1979;3(4):249-51. doi: 10.1007/BF00254740. Cancer Chemother Pharmacol. 1979. PMID: 535135
-
Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.Anticancer Res. 2006 Jan-Feb;26(1B):797-801. Anticancer Res. 2006. PMID: 16739356
-
Preliminary evaluation of myocardial toxicity of 4'-deoxydoxorubicin: experimental and clinical results.Drugs Exp Clin Res. 1985;11(3):223-31. Drugs Exp Clin Res. 1985. PMID: 3836127
-
Doxorubicin: alteration of dose scheduling as a means of reducing cardiotoxicity.Drug Intell Clin Pharm. 1985 Apr;19(4):259-64. doi: 10.1177/106002808501900403. Drug Intell Clin Pharm. 1985. PMID: 3891276 Review.
-
Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy.Eur J Cancer Clin Oncol. 1989 May;25(5):873-82. doi: 10.1016/0277-5379(89)90135-1. Eur J Cancer Clin Oncol. 1989. PMID: 2661240 Review.
Cited by
-
Systolic time intervals: a review of the method in the non-invasive investigation of cardiac function in health, disease and clinical pharmacology.Postgrad Med J. 1983 Jul;59(693):423-34. doi: 10.1136/pgmj.59.693.423. Postgrad Med J. 1983. PMID: 6353394 Free PMC article. Review.
-
Hemodynamic effects of chronic 4'epi-adriamycin administration.Cardiovasc Drugs Ther. 1990 Dec;4(6):1519-23. doi: 10.1007/BF02026501. Cardiovasc Drugs Ther. 1990. PMID: 2081145
-
Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.Br Med J (Clin Res Ed). 1984 Jan 28;288(6413):283-4. doi: 10.1136/bmj.288.6413.283-a. Br Med J (Clin Res Ed). 1984. PMID: 6419896 Free PMC article. Clinical Trial. No abstract available.
-
Scintigraphic evaluation of myocardial uptake of thallium 201 and technetium 99m pyrophosphate utilizing a rat model of chronic doxorubicin cardiotoxicity.Eur J Nucl Med. 1991;18(5):332-8. doi: 10.1007/BF02285461. Eur J Nucl Med. 1991. PMID: 1834467
-
Doxorubicin (adriamycin) cardiomyopathy.West J Med. 1983 Sep;139(3):332-41. West J Med. 1983. PMID: 6356608 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous